<DOC>
	<DOCNO>NCT00398710</DOCNO>
	<brief_summary>This phase II study relapsed/refractory WM patient treat perifosine . It design assess proportion overall confirm response ( CR + PR + MR ) use two-stage phase II study design permit early stopping trial strong evidence study regimen inactive . In addition , assess toxicity drug patient WM . Patients receive perifosine 150 mg qhs daily . Patients assess serum immunoelectrophoresis IgM level least every 4 week .</brief_summary>
	<brief_title>A Phase II Study Perifosine Patients With Relapsed/Refractory Waldenström 's Macroglobulinemia</brief_title>
	<detailed_description>This phase II study relapsed/refractory WM patient treat perifosine . It design assess proportion overall confirm response ( CR + PR + MR ) use two-stage phase II study design permit early stopping trial strong evidence study regimen inactive . In addition , assess toxicity drug patient WM . Patients receive perifosine 150 mg qhs daily . Patients assess serum immunoelectrophoresis IgM level least every 4 week . Patients take three 50 mg tablet perifosine qhs daily ( 28 day cycle ) food . Patients may need anti-emetics and/or anti-diarrheas . All patient continue therapy unless disease progression document two occasion least 1 week apart . Patients progressive disease refuse therapy discontinue protocol . Dose modification toxicity perform . Standard criterion evaluation response WM recommend Second International WM Workshop use study .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Age &gt; = 18 year . Must receive prior therapy WM relapse refractory WM . Any number prior therapy acceptable . Measurable disease , define presence immunoglobulin M ( IgM ) paraprotein minimum IgM level &gt; 2 time upper limit institution 's normal value require 10 % lymphoplasmacytic cell bone marrow . ECOG Performance Status ( PS ) 0 , 1 , 2 . The following laboratory value obtain 14 day prior registration ANC &gt; = 1 x109/L PLT &gt; = 75 x109/L Total bilirubin ≤ 2.0 mg/dL ( If total elevate check direct normal patient eligible . ) AST &lt; = 3 x upper limit normal ( ULN ) Creatinine &lt; = 2 x ULN Ability provide inform consent . Life expectancy &gt; = 12 week . Uncontrolled infection . Other active malignancy . CNS involvement . Cytotoxic chemotherapy ≤ 3 week , biologic therapy ≤ 2 week , corticosteroid ≤ 2 week , prior registration . Patients may receive chronic corticosteroid give disorder WM autoimmune disease . Plasmapheresis consider active therapy use physician 's discretion . Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational . Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device ( IUD ) , abstinence , etc . ) Known HIV positive . Radiation therapy ≤ 2 week prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Waldenström 's Macroglobulinemia</keyword>
	<keyword>Perifosine</keyword>
</DOC>